Connor, Clark & Lunn Investment Management Ltd. - CELLDEX THERAPEUTICS INC NEW ownership

CELLDEX THERAPEUTICS INC NEW's ticker is CLDX and the CUSIP is 15117B202. A total of 161 filers reported holding CELLDEX THERAPEUTICS INC NEW in Q1 2023. The put-call ratio across all filers is 0.51 and the average weighting 0.2%.

Quarter-by-quarter ownership
Connor, Clark & Lunn Investment Management Ltd. ownership history of CELLDEX THERAPEUTICS INC NEW
ValueSharesWeighting
Q3 2023$499,626
-67.4%
18,155
-57.4%
0.00%
-62.5%
Q1 2023$1,534,043
-40.6%
42,636
-26.4%
0.01%
-46.7%
Q4 2022$2,581,049
+13.9%
57,910
-28.2%
0.02%0.0%
Q3 2022$2,267,000
+246.6%
80,650
+565.6%
0.02%
+400.0%
Q3 2021$654,000
+34.6%
12,117
-16.6%
0.00%
+50.0%
Q2 2021$486,000
-25.7%
14,533
-61.1%
0.00%
-50.0%
Q4 2020$654,000
-14.5%
37,346
-27.6%
0.00%
-20.0%
Q3 2020$765,00051,5790.01%
Other shareholders
CELLDEX THERAPEUTICS INC NEW shareholders Q1 2023
NameSharesValueWeighting ↓
Kynam Capital Management, LP 3,200,000$88,064,00014.40%
Octagon Capital Advisors LP 759,898$20,912,3933.21%
TSP Capital Management Group, LLC 251,695$6,926,6452.67%
5AM Venture Management, LLC 310,270$8,538,6302.46%
COMMODORE CAPITAL LP 706,665$19,447,4212.27%
ACUTA CAPITAL PARTNERS, LLC 122,341$3,366,8242.26%
Redmile Group, LLC 1,635,938$45,021,0142.14%
RTW INVESTMENTS, LP 3,463,201$95,307,2922.01%
Eversept Partners, LP 588,143$16,185,6951.37%
Affinity Asset Advisors, LLC 150,000$4,128,0001.16%
View complete list of CELLDEX THERAPEUTICS INC NEW shareholders